<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016145</url>
  </required_header>
  <id_info>
    <org_study_id>Projesq-IPAP</org_study_id>
    <nct_id>NCT01016145</nct_id>
  </id_info>
  <brief_title>Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm</brief_title>
  <official_title>Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate predictors of response to antipsychotic medication
      in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI,
      genetics and neuropsychological profile. Two groups of treatment will be compared: first
      generation antipsychotics vs. second generation antipsychotics. Participants will be
      randomized to one of the groups. Trial duration: 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% responders to first generation antipsychotics vs. % responders to second generation antipsychotics</measure>
    <time_frame>8-12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of treatment abandon and respective causes</measure>
    <time_frame>8-12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Schizophrenia or Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>First generation antipsychotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second generation antipsychotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotics</intervention_name>
    <description>Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg</description>
    <arm_group_label>Second generation antipsychotics</arm_group_label>
    <other_name>Seroquel, Geodon, Zyprexa, Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotics</intervention_name>
    <description>Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.</description>
    <arm_group_label>First generation antipsychotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia or schizoaffective disorder

          -  Age: 18-45 years olde

          -  Less than 10 years of diagnosis

          -  Acute exacerbation of psychotic symptoms

        Exclusion Criteria:

          -  Use of clozapine

          -  Clinical unstable disease

          -  Delirium and cognitive disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monica Kayo, MD</last_name>
    <phone>551130696971</phone>
    <email>monica.kayo@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helio Elkis, PhD</last_name>
    <phone>551130696971</phone>
    <email>helkis@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Psiquiatria - Hospital das Clinicas FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monica Kayo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Helio Elkis</name_title>
    <organization>University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>predictors of response</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>18-45 years old</keyword>
  <keyword>non-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Chlorpromazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

